PROVENTION BIO INC (PRVB) Stock Price, Forecast & Analysis
USA - NASDAQ:PRVB - US74374N1028 - Common Stock
PRVB Key Statistics, Chart & Performance
The current stock price of PRVB is 24.98 USD. In the past month the price increased by 4.26%. In the past year, price increased by 456.35%.
PRVB Latest News, Press Relases and Analysis
PRVB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.64 | 991.57B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.32B | ||
| MRK | MERCK & CO. INC. | 10.7 | 235.48B | ||
| PFE | PFIZER INC | 7.76 | 141.26B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.99 | 93.27B | ||
| ZTS | ZOETIS INC | 18.24 | 51.25B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.23 | 22.13B | ||
| VTRS | VIATRIS INC | 4.5 | 12.24B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.98 | 10.49B | ||
| CORT | CORCEPT THERAPEUTICS INC | 84.86 | 7.87B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.29B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.25B |
Related stock screener links
About PRVB
Company Profile
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. The company is headquartered in Red Bank New Jersey, New Jersey and currently employs 174 full-time employees. The company went IPO on 2018-07-24. The firm's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of systemic lupus erythematosus (SLE) and for the prevention of immunogenicity of biotherapeutics, such as those used in gene therapy. Ordesekimab is a human anti-interleukin 15 (IL-15) mAb for the treatment of gluten-free diet non-responsive celiac disease (NRCD). PRV-101 is a coxsackievirus B (CVB) vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta-cells.
Company Info
PROVENTION BIO INC
55 Broad Street, 2Nd Floor
Red Bank New Jersey NEW JERSEY 07701 US
CEO: Ashleigh Palmer
Employees: 174
Phone: 19084289136.0
PROVENTION BIO INC / PRVB FAQ
What does PRVB do?
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. The company is headquartered in Red Bank New Jersey, New Jersey and currently employs 174 full-time employees. The company went IPO on 2018-07-24. The firm's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of systemic lupus erythematosus (SLE) and for the prevention of immunogenicity of biotherapeutics, such as those used in gene therapy. Ordesekimab is a human anti-interleukin 15 (IL-15) mAb for the treatment of gluten-free diet non-responsive celiac disease (NRCD). PRV-101 is a coxsackievirus B (CVB) vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta-cells.
What is the current price of PRVB stock?
The current stock price of PRVB is 24.98 USD. The price increased by 3.1% in the last trading session.
Does PRVB stock pay dividends?
PRVB does not pay a dividend.
How is the ChartMill rating for PROVENTION BIO INC?
PRVB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists PRVB stock?
PRVB stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of PRVB stock?
PROVENTION BIO INC (PRVB) operates in the Health Care sector and the Pharmaceuticals industry.
PRVB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PRVB. When comparing the yearly performance of all stocks, PRVB is one of the better performing stocks in the market, outperforming 99.85% of all stocks.
PRVB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRVB. PRVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PRVB Financial Highlights
Over the last trailing twelve months PRVB reported a non-GAAP Earnings per Share(EPS) of -1.6. The EPS increased by 12.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.19 |
PRVB Forecast & Estimates
12 analysts have analysed PRVB and the average price target is 24.48 USD. This implies a price decrease of -2% is expected in the next year compared to the current price of 24.98.
For the next year, analysts expect an EPS growth of -18.96% and a revenue growth 372.61% for PRVB